FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070291488> ?p ?o ?g. }

• W2070291488 endingPage "130" @default.
• W2070291488 startingPage "124" @default.
• W2070291488 abstract "Trimetrexate glucuronate (TMTX), a nonclassical folate antagonist, has been evaluated clinically on several schedules. We have studied TMTX administered as an iv bolus for 5 consecutive days, every 3 weeks in 35 patients with advanced solid tumors. Drug was given at doses ranging from 7.6 to 18.8 mg/m2. The maximal tolerated dose was 13.1 mg/m2 per day × 5 for patients without prior myelotoxic treatment and 7.6 mg/m2 per day × 5 for previously treated patients. Because of wide individual differences in drug tolerance, dose escalation in 25% increments is recommended for patients not experiencing toxic effects. The dose-limiting toxicity was neutropenia. Rash and mucositis were also significant TMTX concentrations were measured 1 and 24 hours after each dose, and the data were fit by use of a one-compartment pharmacokinetic model. With this simplified sampling and modeling scheme, the mean total body clearance (± SD) of trimetrexate was 31 ± 20 mL/min per m2 and the volume of distribution was 13 ± 7 L/m2. Mean plasma concentrations 1 hour after a dose were 1.12, 2.43, 3.33, and 3.25 μmoI/L at 7.6, 9.1, 10.9, and 13.1 mg/m2, respectively. The mean TMTX concentration (± SD) 24 hours after a dose was 114 ± 87 nmol/L. The mean area under the concentration-versus-time curve at 13.1 mg/m2 was 2,266 μmol-min/L. The drug concentration 1 hour after the first dose and the area under the concentration-versus-time curve were highly correlated with leukopenia and thrombocytope-nia (r = .6 and .65 and P = .0007 and .0001, respectively). The maximal tolerated dose on the daily × 5 schedule was 30% of the dose tolerated on an iv bolus schedule. The choice of drug schedule for clinical trials when murine and human pharmacokinetics differ is discussed. Phase II trials are under way with both the iv bolus and the daily × 5 schedules." @default.
• W2070291488 created "2016-06-24" @default.
• W2070291488 creator A5002365746 @default.
• W2070291488 creator A5003214440 @default.
• W2070291488 creator A5003528816 @default.
• W2070291488 creator A5011905014 @default.
• W2070291488 creator A5019357584 @default.
• W2070291488 creator A5023653126 @default.
• W2070291488 creator A5057225248 @default.
• W2070291488 creator A5083361615 @default.
• W2070291488 date "1989-01-18" @default.
• W2070291488 modified "2023-10-16" @default.
• W2070291488 title "Phase I Trial of Trimetrexate Glucuronate on a Five-Day Bolus Schedule: Clinical Pharmacology and Pharmacodynamics" @default.
• W2070291488 doi "https://doi.org/10.1093/jnci/81.2.124" @default.
• W2070291488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2909752" @default.
• W2070291488 hasPublicationYear "1989" @default.
• W2070291488 type Work @default.
• W2070291488 sameAs 2070291488 @default.
• W2070291488 citedByCount "31" @default.
• W2070291488 crossrefType "journal-article" @default.
• W2070291488 hasAuthorship W2070291488A5002365746 @default.
• W2070291488 hasAuthorship W2070291488A5003214440 @default.
• W2070291488 hasAuthorship W2070291488A5003528816 @default.
• W2070291488 hasAuthorship W2070291488A5011905014 @default.
• W2070291488 hasAuthorship W2070291488A5019357584 @default.
• W2070291488 hasAuthorship W2070291488A5023653126 @default.
• W2070291488 hasAuthorship W2070291488A5057225248 @default.
• W2070291488 hasAuthorship W2070291488A5083361615 @default.
• W2070291488 hasConcept C111113717 @default.
• W2070291488 hasConcept C112705442 @default.
• W2070291488 hasConcept C126322002 @default.
• W2070291488 hasConcept C2776694085 @default.
• W2070291488 hasConcept C2777063308 @default.
• W2070291488 hasConcept C2778496288 @default.
• W2070291488 hasConcept C43376680 @default.
• W2070291488 hasConcept C71924100 @default.
• W2070291488 hasConcept C76318530 @default.
• W2070291488 hasConcept C98274493 @default.
• W2070291488 hasConceptScore W2070291488C111113717 @default.
• W2070291488 hasConceptScore W2070291488C112705442 @default.
• W2070291488 hasConceptScore W2070291488C126322002 @default.
• W2070291488 hasConceptScore W2070291488C2776694085 @default.
• W2070291488 hasConceptScore W2070291488C2777063308 @default.
• W2070291488 hasConceptScore W2070291488C2778496288 @default.
• W2070291488 hasConceptScore W2070291488C43376680 @default.
• W2070291488 hasConceptScore W2070291488C71924100 @default.
• W2070291488 hasConceptScore W2070291488C76318530 @default.
• W2070291488 hasConceptScore W2070291488C98274493 @default.
• W2070291488 hasIssue "2" @default.
• W2070291488 hasLocation W20702914881 @default.
• W2070291488 hasLocation W20702914882 @default.
• W2070291488 hasOpenAccess W2070291488 @default.
• W2070291488 hasPrimaryLocation W20702914881 @default.
• W2070291488 hasRelatedWork W1540839883 @default.
• W2070291488 hasRelatedWork W1541103017 @default.
• W2070291488 hasRelatedWork W1758514097 @default.
• W2070291488 hasRelatedWork W1836451026 @default.
• W2070291488 hasRelatedWork W1979719945 @default.
• W2070291488 hasRelatedWork W2078502580 @default.
• W2070291488 hasRelatedWork W2102649824 @default.
• W2070291488 hasRelatedWork W2137351715 @default.
• W2070291488 hasRelatedWork W2141193653 @default.
• W2070291488 hasRelatedWork W2142080078 @default.
• W2070291488 hasVolume "81" @default.
• W2070291488 isParatext "false" @default.
• W2070291488 isRetracted "false" @default.
• W2070291488 magId "2070291488" @default.
• W2070291488 workType "article" @default.